Roche’s Gazyva/Gazyvaro receives US FDA approval for the treatment of lupus nephritis: Basel Wednesday, October 22, 2025, 10:00 Hrs [IST] Roche announced that the US Food and Dr ...
With the lupus treatment landscape poised for a shake-up, Roche is hitting t | Early Monday, Roche announced that the FDA ...
FDA approval based on superiority of Gazyva/Gazyvaro over standard therapy alone, as shown in phase II NOBILITY and phase III REGENCY data1,2Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody ...
Title: Tenapanor Improves Bowel Movements in Patients with End-Stage Kidney Disease and Mild to Severe Constipation Authors: Steven Fishbane, Suling Zhao, Yang Yang, Susan Edelstein, David M. Spiegel ...
In APPLAUSE-IgAN final analysis, Fabhalta demonstrated statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope vs. placebo over two years1eGFR ...
These upcoming presentations underscore the breadth and versatility of our ACT-UP1 platform,” said Xuehai Liang, Ph.D., Chief Executive Officer of Arnatar Therapeutics. “By demonstrating the ability ...
5d
F. Hoffmann-La Roche Ltd: CHMP recommends EU approval of Roche's Gazyva/Gazyvaro for lupus nephritis
Positive recommendation based on phase II NOBILITY and phase III REGENCY data showing Gazyva/Gazyvaro's superiority over standard therapy alone1,2 Gazyva/Gazyvaro is the only anti-CD20 antibody to ...
Gazyva/Gazyvaro is the only anti-CD20 antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study2 Lupus nephritis is a debilitating condition that ...
KCEN-TV on MSN
'It's a miracle' | Groesbeck man's miraculous recovery defies expectations and inspires hope
After facing severe heart issues, Danny Dupree has seen a miraculous recovery, canceling his need for a transplant and inspiring others in similar situations.
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
Novo Nordisk's Alzheimer's trial really is like a lottery ticket. If it wins, the company gains a transformational new market ...
Omeros Corporation maintained with Strong Buy rating after securing a $2.1 billion partnership with Novo Nordisk for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback